NFE2L2 and Cirrhosis: A randomized, double-blind, placebo - controlled phase II trial demonstrated that reductions in inflammation, oxidative stress and fibrosis could be achieved using oltipraz (OPZ), nuclear factor - erythroid – 2 - related factor 2 (Nrf2) activator in patients with liver fibrosis or cirrhosis (11).